DiaMedica Therapeutics (DMAC) Cash from Investing Activities (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Cash from Investing Activities for 9 consecutive years, with $8.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Investing Activities fell 7.97% year-over-year to $8.2 million; the trailing twelve-month figure through Jun 2026 stood at -$11.6 million (down 176.6% YoY), and the FY2025 full-year result was -$2.2 million, down 125.6% from the prior year.
• Cash from Investing Activities climbed to $8.2 million in Q2 2026 per DMAC's latest filing, from -$2.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $9.0 million in Q2 2025 and bottomed at -$28.1 million in Q2 2023.
• Historically, Cash from Investing Activities has averaged $318888.9 across 5 years, with a median of $3.4 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities soared 24700.0% in 2022, then slumped 1212.66% in 2023.
• Over 5 years, Cash from Investing Activities stood at $4.7 million in 2022, then increased by 29.64% to $6.1 million in 2023, then declined by 15.01% to $5.2 million in 2024, then soared by 53.6% to $8.0 million in 2025, then rose by 3.1% to $8.2 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $8.2 million, -$2.1 million, and $8.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.